Author Correction: Lower urinary dysfunction as a long-term effect of childhood vincristine treatment, with potential influences by sex and dose
Nao Iguchi, Ali Teimouri, Duncan T. Wilcox, Anna P. Malykhina, Nicholas G. Cost
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmacology and Obesity Treatment
Correction to: Scientific Reports 10.1038/s41598-024-65313-9, published online 01 July 2024
The original version of this Article contained an error. In the Materials and Methods section, under the subsection ‘In Vitro Bladder Strip Contractility Measurements,’ the concentration was incorrect.
“In the second set of experiment (Fig. 5A), bladder strips (N=9–10 mice per group) were used to evaluate impacts of compound 48/80 (C-48/80, 50 µg/ml, Sigma-Aldrich, St. Louis, MO, USA), and histamine (250 µM, Sigma-Aldrich) and capsaicin (10 µM, transient receptor potential vanilloid 1 channel (Trpv1) agonist, Cayman Chemical, Ann Arbor, MI, USA) in the presence or absence of fexofenadine HCl, a histamine receptor 1 (Hrh1) inhibitor (10 µM, Cayman Chemical).”
now reads:
“In the second set of experiment (Fig. 5A), bladder strips (N=9–10 mice per group) were used to evaluate impacts of compound 48/80 (C-48/80, 50 µg/ml, Sigma-Aldrich, St. Louis, MO, USA), and histamine (150 µM, Sigma-Aldrich) and capsaicin (10 µM, transient receptor potential vanilloid 1 channel (Trpv1) agonist, Cayman Chemical, Ann Arbor, MI, USA) in the presence or absence of fexofenadine HCl, a histamine receptor 1 (Hrh1) inhibitor (10 µM, Cayman Chemical).”
The original article has been corrected.